Kyverna ’s $319M IPO adds to fervor for autoimmune cell therapies

Cal­i­for­nia biotech Kyver­na Ther­a­peu­tics will gar­ner $319 mil­lion from its Thurs­day morn­ing Nas­daq de­but as it rides a small but wel­come wave of in­vestor en­thu­si­asm for ini­tial pub­lic of­fer­ings. The mid-stage cell ther­a­py mak­er priced at $22 apiece, sell­ing 14.5 mil­lion…#kyverna #unlock

Source: Reuters: Health - February 8, 2024 Category: Consumer Health News Source Type: news